1.
Pediatr Dermatol
; 34(3): 337-341, 2017 May.
Article
in English
| MEDLINE
| ID: mdl-28523881
ABSTRACT
Vemurafenib is increasingly being used to treat nonmelanoma tumors that are positive for the BRAF V600E mutation. We report three children who presented with panniculitis induced by vemurafenib while undergoing treatment for central nervous system tumors and review the literature.
Subject(s)
Antineoplastic Agents/adverse effects , Central Nervous System Neoplasms/drug therapy , Indoles/adverse effects , Panniculitis/chemically induced , Sulfonamides/adverse effects , Adolescent , Child , Humans , Male , Vemurafenib
2.
J Am Acad Dermatol
; 75(4): e169, 2016 10.
Article
in English
| MEDLINE
| ID: mdl-27646769
